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Abstract
Transitional cell carcinoma (TCC) of urinary bladder belongs to glutathione S-transferase P1 (GSTP1) over-
expressingtumors.UpregulatedGSTP1inTCCisrelatedtoapoptosisinhibition.ThisantiapoptoticeffectsofGSTP1
might be mediated through protein:protein interaction with c-Jun NH2-terminal kinase (JNK). Herein, we analyzed
whetheradirectlinkbetweenGSTP1andJNKexistsinTCC.ThepresenceofGSTP1/JNKcomplexeswasanalyzed
by immunoprecipitation and Western blotting in 20 TCC specimens, obtained after surgery. Co-localization of
GSTP1 and JNK was also investigated in the 5637 TCC cell line by immunofluorescence confocal microscopy. By
means of immunoprecipitation we show for the first time the presence of GSTP1/JNK complexes in all TCC samples
studied. A co-localization of GSTP1 and JNK was also demonstrated in the 5637 TCC cell line by means of confocal
microscopy. Protein-protein interactions, together with co-localization between GSTP1 and JNK provide evidence
that GSTP1 most probably inhibits apoptosis in TCC cells by non-covalent binding to JNK.
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Theglutathionetransferasesareamultigenefamilyof
isozymes that catalyze the nucleophilic attack of the sulfur
atom of glutathione on electrophilic groups of substrate
molecules (Hayes and Strange, 2000). Glutathione trans-
ferase P1 (GSTP1) is the most prevalent in mammalian
cells (Townsend and Tew, 2003). GSTP1 is overexpressed
in many tumors, including transitional cell carcinoma
(TCC) of urinary bladder, where its activity and expression
correlate with tumor stage and grade (Berendsen et al.,
1997; Townsend and Tew, 2003; Simic et al., 2005). Be-
cause of the defined role of GST in drug metabolism, ele-
vated expression of GSTP1 in tumors has been frequently
associated with detoxification reactions. Nevertheless,
GSTP1 overexpression has been found in drug resistant
cells, even in instances where there is no evidence that the
selecting drug is a substrate for GSTP1 (Gate and Tew,
2001; Townsend and Tew, 2003). Recently, a new insight
into a functional link between upregulated GSTP1 and the
malignant phenotype has been suggested from growing ev-
idence that GSTs are also involved in the regulation of
stress signaling and resistance to apoptosis by mechanisms
independent of their catalytic activity; this regulatory role
depending on cellular redox status (Wang et al., 2001;
AdlerandPincus,2004;Simicetal.,2009).InTCC,theox-
idant-antioxidant balance favors the reduced state, as in-
creased levels of glutathione, the major cellular nonprotein
antioxidant, together with upregulated antioxidant en-
zymeshavebeenobservedinthissetting(Yangetal.,1997;
Savic-Radojevic et al., 2007). High intracellular thiol lev-
els and the absence of oxidative stress promote the exis-
tence of GSTP1 in monomeric form, while catalitically
active GSTP1 is normally dimerized. Redox-active mono-
meric GSTP1 subunits inhibit c-Jun NH2-terminal kinase
(JNK), an enzyme that triggers the apoptotic cascade in
severalcancercelllines(Wangetal.,2001).Fromourpoint
of view, high antioxidant capacity also promotes an antia-
poptoticroleofGSTP1inTCC.Infavorofsuchahypothe-
sis are recent data showing a significant negative correla-
tion between GSTP1 and cleaved caspase 3 expression in
human TCC specimens (Pljesa-Ercegovac et al., 2009).
Nevertheless, the direct link between GSTP1 and JNK in
TCC still has to be confirmed. Herein, we analyzed the
presence of GSTP1/JNK complexes in specimens of tumor
tissue of the urinary bladder obtained from 20 patients with
TCC after radical cystectomy, as well as in the 5637 TCC
cell line. Specimens of tumor tissue were taken in the oper-
Genetics and Molecular Biology, 33, 3, 460-462 (2010)
Copyright © 2010, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to Marija Pljesa-Ercegovac. Faculty of Medi-
cine, Institute of Medical and Clinical Biochemistry, University of
Belgrade, Pasterova 2, 11000 Belgrade, Serbia. E-mail:
marijaercegovac@med.bg.ac.rs.
Short Communicationating theatre in the presence of a clinical pathologist who
performed the histopathology examination. All patients
gave informed consent to enter the study. The ethics com-
mittee approved the use of human tissue for research.
Tumor samples were washed in cold saline, frozen in
liquid nitrogen and stored at -80 °C until use. Immuno-
precipitation experiments were performed using the pri-
mary antibody against JNK (Sigma-Aldrich, St. Louis,
USA) and the Protein A-agarose (Roche Applied Science,
Mannheim, Germany). Samples were homogenized with
the lysis buffer provided by the manufacturer and centri-
fuged at 100.000 x g for 45 min at 4 °C. Cytosolic fractions
of TCC specimens were incubated with 2 L of anti-JNK
antibody overnight at 4 °C. Immunoblots were then probed
with the anti-GSTP1 antibody (Sigma-Aldrich, St. Louis,
USA). JNK expression was determined on the same mem-
brane after stripping off the immune complex for the detec-
tion of GSTP1. Immunoblot analysis showed an absence of
non-specific binding of the JNK antibody to GSTP1. Con-
trol immunoprecipitations, that were performed in the ab-
sence of anti-JNK antibody, ruled out possible unspecific
pull-down of GSTP1. Confocal microscopy on cells of the
5637 cell line was performed using anti-GSTP1 antibody
followed by FITC-conjugated secondary antibody (Dako,
Glostrup, Danmark), as well as anti-JNK antibody fol-
lowed by TRITC-conjugated secondary antibody (Dako,
Glostrup, Danmark). Coverslips were mounted with fluo-
rescent mounting medium (Dako, Glostrup, Danmark),
observed and photographed under confocal scanning mi-
croscope (Leica LCS). The specificity of the primary anti-
bodies used was previously confirmed by Western blot
analysis. Control experiments for non-specific binding
were performed in parallel by omission of the primary anti-
body.
Immunoprecipitation, followed by Western blotting
showed the presence of GSTP1/JNK complexes in all TCC
samples studied (Figure 1A). Furthermore, co-localization
ofGSTP1andJNKwasconfirmedin5637TCCcelllineby
means of immunofluorescence confocal microscopy (Fig-
ure 1B). These results are in agreement with data of Adler
and Pincus (2004) who performed molecular dynamics in-
vestigations on the 3-dimensional structure of GSTP1, free
and bound to an inhibitor, that blocks its ability to inhibit
JNK activation (Adler and Pincus, 2004). Four putative do-
mains are involved in the interaction between GSTP1 and
JNK. Two of these are involved in GSTP1 binding to JNK,
whereas the other two affect phosphorylation of JNK. The
proposed mechanism by which GSTP1 inhibits activation
of JNK is by either blocking phosphorylation of JNK or by
promoting dephosphorylation of phosphorylated JNK
(Adler and Pincus, 2004). In this manner, JNK is prevented
from activating downstream targets in the apoptotic path-
way, such as c- Jun. Our results support such a hypothesis,
because the activated JNK signal was not detected in our
immunoprecipitation experiments.
The presence of GSTP1/JNK complex has also been
reported in human leukemia, hepatic carcinoma and neuro-
blastoma cells (Ricci et al., 2005; Turella et al., 2005; Cui
Pljesa-Ercegovac et al. 461
Figure 1 - (A) Co-immunoprecipitation of GSTP1 with JNK in human TCC specimens. Immunoprecipitation was performed using protein A-agarose to
retain JNK/GSTP1 complexes. Anti-JNK antibody and polyclonal anti-GSTP1 antibody were used for Western blot analysis. (B) Confocal microscopy
images of human 5637 TCC cells after incubation with anti-GSTP1 antibody followed by FITC-conjugated secondary antibody (I); after incubation with
anti-JNK antibody followed by TRITC-conjugated secondary antibody (II); Image showing co-localization of GSTP1 with JNK (III). Coverslips were
mounted with fluorescent mounting medium, observed and photographed under confocal scanning microscope.et al., 2008; Castro-Caldas et al., 2009). Therefore, it is
possiblethatinthesecellsGSTP1mayactasaninhibitorof
apoptosis, controlling JNK catalytic activity. In addition to
enhancement of tumor progression, upregulated GSTP1
expression in TCC might also limit the efficacy of chemo-
therapeutic agents that act by inducing apoptosis via the
JNK pathway (Wang et al., 2001; Townsend and Tew,
2003;Burgetal.,2006;LoandAli-Osman,2007).Todate,
severalchemotherapeuticagentsthatarebeingusedinvari-
ous stages of TCC, such as mytomicine c, adriamycine and
cysplatin,induceapoptosisintumorcellsviatheJNKpath-
way. We believe that the presence of GSTP1 in complexes
with JNK limits the efficacy of intravesicular and systemic
chemotherapy in bladder cancer, affecting patients’ sur-
vival. In order to improve the response to chemotherapy it
seems reasonable that novel small-molecule GSTP1-tar-
getedagents,whichweredevelopedtoovercomeresistance
to treatment in ovarian, non-small-cell lung, breast, and
colorectal cancers, can also be used to sensitize TCC tumor
cells(Tew,2005;Turellaetal.,2005;Vergoteetal.,2007).
In conclusion, this study adds to the generality of the
interaction between GSTP1 and JNK as a contributing fac-
tor to TCC phenotype and might have important implica-
tions in the treatment of these tumors.
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